Investing RAD 202 receives approval to start Phase 1 therapeutic trial December 20, 2024 Share Share on Facebook Share on Twitter Pinterest Email Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com 0 Prev Post Westgold Shares Scoping Study for Expansion of Fortnum Gold Operation December 20, 2024 Next Post PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis December 20, 2024 Related Posts RETRANSMISSION: LaFleur Minerals Upsizes LIFE and Flow-Through Unit Offerings December 19, 2025 Silver Dollar Resources December 19, 2025 Pinnacle Closes First Tranche of Private Placement December 19, 2025
